Table 4.
Association of XPC polymorphisms with therapeutic response to neoadjuvant chemotherapy in breast cancer patients
| Variable | No. | RECIST | P [Link] | OR (95% CI)‡ | |
|---|---|---|---|---|---|
| CR and PR (%) | SD and PD (%) | ||||
| XPC Ala499Val | 72 | ||||
| CC | 24 | 9 (37.5) | 15 (62.5) | 1.00 (ref.) | |
| CT | 33 | 16 (48.5) | 17 (51.5) | 0.409 | 0.637 (0.218‐1.862) |
| TT | 15 | 11 (73.3) | 4 (26.7) | 0.029 | 0.218 (0.053‐0.895) |
| CT+TT | 48 | 27 (58.3) | 21 (41.7) | 0.137 | 0.467 (0.171‐1.274) |
| XPC Lys939Gln | 72 | ||||
| AA | 21 | 6 (28.6) | 15 (71.4) | 1.00 (ref.) | |
| AC | 42 | 23 (54.8) | 19 (45.2) | 0.049 | 0.330 (0.107‐1.018) |
| CC | 9 | 7 (77.8) | 2 (22.2) | 0.013 | 0.114 (0.018‐0.716) |
| AC+CC | 51 | 30 (58.8) | 21 (41.2) | 0.020 | 0.280 (0.093‐0.840) |
†P‐values were calculated from χ2‐tests or Fisher's exact test. ‡Odds ratio (OR) and 95% confidence interval (CI) values were calculated by unconditional logistic regression adjusted for age and menopausal status. CR, complete response; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; ref., reference; SD, stable disease.